Skip to content

Quantitative Automated Lesion Detection of Traumatic Brain Injury

Quantitative Automated Lesion Detection of TBI

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01022307
Acronym
QALD
Enrollment
212
Registered
2009-12-01
Start date
2009-05-31
Completion date
2014-10-31
Last updated
2016-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

behavioral data acquisition, MRI

Brief summary

The investigators propose to develop quantitative automated lesion detection (QALD) procedures to identify brain damage following traumatic brain injury more accurately than is possible with a normal magnetic resonance imaging (MRI) scans. These procedures require about 1 hour of imaging in an MRI scanner. Subjects will also undergo about 2 hours of cognitive tests. The investigators will compare the results of the cognitive tests with those from MRI scanning to determine what brain regions are responsible for superior performance and for performance decrements.

Detailed description

Because of their non-focal nature, TBI-related brain lesions are difficult to detect and quantify with traditional MRI. In the current research program the investigators propose to develop quantitative automated lesion detection (QALD) procedures to (1) clarify the nature and distribution of tissue damage following mild, moderate and severe TBI (2) improve the capability of detecting, quantifying, and localizing TBI brain damage in individual patients and (3) correlate quantitative measures of brain damage in individual TBI patients with neuropsychological deficits in attention, memory, and executive function. QALD detects abnormal tissue parameters in the diseased brain through statistical comparisons with a normative database. Preliminary results show that QALD is capable of detecting highly significant abnormalities in the brains of TBI patients with normal clinical MRI scans. QALD will be further enhanced and tested with a larger database and including brain images acquired with four different imaging sequences (T1, T2, DTI and fluid-attenuated inversion recovery or FLAIR) from 100 control subjects. Data analysis will incorporate advanced cortical surface mapping techniques to quantify gray matter tissue parameters and thickness in 34 distinct cortical regions in each hemisphere. In addition, cortical fiber projections will be quantified with DTI and FLAIR analysis of white matter lying below the cortical surface. Subcortical fiber tracts critical for complex cognitive operations will be analyzed with voxel-based morphometry and with improved region of interest algorithms to define fiber tract boundaries. Tissue properties in critical subcortical structures (e.g., the hippocampus) will be quantified after automatic parcellation of these brain regions. The investigators will also test the control subjects on a battery of neuropsychological tests (NPTs) and correlate variations in the size, myelination, and tissue properties of normal cortical and subcortical structures with cognitive performance. Then, the investigators will gather identical imaging data in 99 TBI patients divided into three groups (mild, moderate and severe TBI) in order to characterize the average pattern of damage caused by TBIs of different severity. Next, the investigators will quantify lesions in individual TBI patients and describe the variability of lesion patterns in the different severity groups. In parallel, the investigators will develop further multimodal analysis techniques to combine statistical information from different imaging sequences to improve lesion-detection sensitivity to co-localized abnormalities evident with different imaging protocols. In addition, the investigators will test patients with NPTs and analyze the relationship between brain damage, cognitive performance and self-assessments of outcome in order to improve the prognostic value of neuroradiological studies of TBI.

Interventions

None listed

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Control subjects from 18-50. * Patients from 18-50 who have suffered TBI.

Exclusion criteria

* Substance abuse. * Irremedial sensory deficits (blindness, deafness). * Primary psychiatric disorder. * Neurological disease unrelated to TBI.

Design outcomes

Primary

MeasureTime frameDescription
Performance on Trail-making Test, Part BSingle session generally several years after TBI depending on time of recruitment of subjects.z-score based on response time, regressed for age and computer use

Countries

United States

Participant flow

Participants by arm

ArmCount
Group 1: no History of TBI
184 participants with no history of traumatic brain injury (TBI).
184
Group 2: With a History of TBI
28 patients with a history of TBI. Most of these patients had suffered mild TBI. 24 underwent multimodal MR imaging.
24
Total208

Baseline characteristics

CharacteristicGroup 2: With a History of TBIGroup 1: no History of TBITotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
24 Participants184 Participants208 Participants
Age, Continuous36.16 years
STANDARD_DEVIATION 29
40.03 years
STANDARD_DEVIATION 24.2
39.2 years
STANDARD_DEVIATION 25.8
Gender
Female
1 participants82 participants83 participants
Gender
Male
23 participants98 participants121 participants
Region of Enrollment
United States
24 participants184 participants208 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 1840 / 28
serious
Total, serious adverse events
0 / 1840 / 28

Outcome results

Primary

Performance on Trail-making Test, Part B

z-score based on response time, regressed for age and computer use

Time frame: Single session generally several years after TBI depending on time of recruitment of subjects.

Population: z-score

ArmMeasureValue (MEAN)Dispersion
Group 1: no History of TBIPerformance on Trail-making Test, Part B-0.02 z-scoreStandard Deviation 0.98
Group 2: With a History of TBIPerformance on Trail-making Test, Part B0.18 z-scoreStandard Deviation 0.95
Comparison: F-test evaluating effects of Groupp-value: <0.04F-test

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026